[Clinical Study of Blinatumomab in the Treatment of Adult Relapsed/Refractory Ph-Negative Acute B-Lymphoblastic Leukemia].

MLA

Ouyang, Min, et al. “[Clinical Study of Blinatumomab in the Treatment of Adult Relapsed/Refractory Ph-Negative Acute B-Lymphoblastic Leukemia].” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 31, no. 5, Jan. 2023, pp. 1352–57. EBSCOhost, https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.05.016.

APA

Ouyang, M., Zhang, Y.-Y., Shi, L., Liu, J.-X., Wang, C.-J., Wang, F., Zhang, Y., Li, Y., Zhang, M.-X., Hu, W.-Q., Ren, H.-Y., & Jiang, B. (2023). [Clinical Study of Blinatumomab in the Treatment of Adult Relapsed/Refractory Ph-Negative Acute B-Lymphoblastic Leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 31(5), 1352–1357. https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.05.016

Chicago

Ouyang, Min, Ya-Yun Zhang, Lin Shi, Jian-Xin Liu, Chun-Jian Wang, Fang Wang, Yao Zhang, et al. 2023. “[Clinical Study of Blinatumomab in the Treatment of Adult Relapsed/Refractory Ph-Negative Acute B-Lymphoblastic Leukemia].” Zhongguo Shi Yan Xue Ye Xue Za Zhi 31 (5): 1352–57. doi:10.19746/j.cnki.issn.1009-2137.2023.05.016.